Magic™ Humanized PD-L1/CTLA-4 Dual Immune Checkpoint Knock-In Mice

  • Check with publisher
  • Published date: February 11, 2020
    • Shirley, New York, United States

Monoclonal antibodies (mAbs) are a rapidly growing class of human therapeutics representing an increasing number of drugs under development. Monoclonal antibodies have been used for treating cancer, autoimmune diseases, and infectious diseases in clinical practice. Antibody therapy directly targeted several immune checkpoints is demonstrating significant success in the past few years. Particularly, cancer therapy based on monoclonal antibodies against checkpoints of immune reaction is now regarded as a breakthrough method in oncological immunology. Nowadays, it is an urgent need to increase success rates of this immunotherapeutic approach and to extend it to more cancer types. Creative Biolabs, who always focuses on drug discovery and animal model, has successfully launched and established an exclusive Magic™ “humanized” animal model platform, which can provide the humanized PD-L1/CTLA-4 dual immune checkpoint knock-in mice to our clients all over the world. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pd-l1-ctla-4-dual-immune-checkpoint-knock-in-mice.htm .

Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • PLGA, Poly(lactic-co-glycolic acid)s

    PLGA, Poly(lactic-co-glycolic acid)s

    Biomedical Sciences Shirley (New York) November 24, 2020 Check with publisher

    Solid phase drug delivery/implantable systems, CD Bioparticles provides PLGA, Poly(lactic-co-glycolic acid)s with a PLGA molecular weight of Mw 55,000-65,000 Da DL for drug delivery. https://www.cd-bioparticles.net/p/496/plga

  • PLGA-DPE, Poly(lactic-co-glycolic acid)s

    PLGA-DPE, Poly(lactic-co-glycolic acid)s

    Biomedical Sciences Shirley (New York) November 24, 2020 Check with publisher

    Solid phase drug delivery/implantable systems. CD Bioparticles provides PLGA-DPE, Poly(lactic-co-glycolic acid)s with a PLGA molecular weight of Mw 40,000 -60,000 Da for drug delivery. https://www.cd-bioparticles.net/p/485/plga-dpe.

  • PLGA, Poly(lactic-co-glycolic acid)s

    PLGA, Poly(lactic-co-glycolic acid)s

    Biomedical Sciences Shirley (New York) November 24, 2020 Check with publisher

    Solid phase drug delivery/implantable systems. CD Bioparticles provides PLGA, Poly(lactic-co-glycolic acid)s with a PLGA molecular weight of Mw 35,000-45,000 Da DL for drug delivery. https://www.cd-bioparticles.net/p/472/plga